Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination

View ORCID ProfilePhillip L.R. Nicolson, Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Steve P. Watson, Gillian C. Lowe, William A. Lester
doi: https://doi.org/10.1101/2021.08.17.21262138
Phillip L.R. Nicolson
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Phillip L.R. Nicolson
  • For correspondence: p.nicolson@bham.ac.uk s.p.watson@bham.ac.uk
Samantha J. Montague
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher W. Smith
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare S. Lodwick
3Department of Haematology, Worcester Acute Hospitals NHS Trust, Worcester WR5 1DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Stoneley
4Department of Blood Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Roberts
4Department of Blood Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve P. Watson
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian C. Lowe
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Lester
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Anti-Platelet Factor 4 (PF4) IgG antibodies that activate platelets via FcγRIIa have been shown to be an important part of the pathophysiology of vaccine-induced immune thrombocytopenia and thrombosis (VITT). There is now extensive literature on its presentation and initial management. There is no literature however on what happens to these patients following discharge.

Methods We collected clinical data and samples from seven patients presenting with VITT and followed them up for 82-145 days. We also collected clinical samples from them at last follow-up. Testing for anti-PF4/heparin antibodies was done using an anti-PF4/heparin enzymatic immunoassay. Flow Cytometry was used to look at FcγRIIa levels on patient platelets. Light Transmission Aggregometry with patient serum and healthy donor / patient platelets was used to analyse platelet responsiveness, in the presence and absence of PF4.

Findings All patients were discharged on direct oral anticoagulants. Two patients remain completely symptom free, three have ongoing headaches, two have residual neurological deficits. Two patients developed mild thrombocytopenia and worsening headache (but without cerebral venous sinus thrombosis) and were retreated, one of these with rituximab. All patients, except the one treated with rituximab, had similar anti-PF4 antibody titres at 80-120 days to their levels at diagnosis. Platelets from patients at follow-up had normal levels of FcγRIIa and had normal responses to thrombin and collagen-related-peptide. Patient serum from diagnosis strongly activated healthy donor platelets in the presence of PF4. Serum from follow-up was much weaker at stimulating platelets, even in the presence of PF4.

Interpretation This study shows that despite similar PF4 antibody titres at diagnosis and during follow-up, there are further differences in patient serum, that are not apparent from currently used testing, that result in lower levels of platelet activation during the follow-up period. Further understanding of these factors are important in order to assess duration of anticoagulation for these patients.

Funding This work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF) and by a National Institute for Health Research (NIHR) grant.

Key points

  1. PF4 antibody titres do not reduce up to 4-months post ChAdOx1 nCoV-19 in patients with VITT

  2. Despite similar PF4 antibody titres, diagnostic serum is more potent at activating platelets in the presence of PF4 than follow-up serum.

Competing Interest Statement

PLRN and SPW have received research grants from Novartis, Principia and Rigel Pharmaceuticals. PLRN has had honoraria from Bayer, Grifols and Takeda.

Funding Statement

This work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF) and a National Institute for Health Research (NIHR) grant. SPW holds a BHF Chair (CH03/003).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Patients presenting with thrombosis and thrombocytopenia, occurring after AZD1222 vaccination were recruited. Informed consent was provided by the patients or by their next of kin in those who lacked capacity. Collection of blood from these patients (including those lacking capacity) was approved under research ethics granted to the University of Birmingham Human Biomaterial Resource Centre (North West, Haydock Research Ethics Committee, reference: 15/NW/0079, amendment 3, 19/11/2018). Ethical approval for collecting blood from healthy volunteers was granted by Birmingham University Internal Ethical Review Committee (reference: ERN_11-0175, assessed 22/3/2021). All studies were performed in line with the Declaration of Helsinki.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Individual participant data will not be made available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 23, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
Phillip L.R. Nicolson, Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Steve P. Watson, Gillian C. Lowe, William A. Lester
medRxiv 2021.08.17.21262138; doi: https://doi.org/10.1101/2021.08.17.21262138
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
Phillip L.R. Nicolson, Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Steve P. Watson, Gillian C. Lowe, William A. Lester
medRxiv 2021.08.17.21262138; doi: https://doi.org/10.1101/2021.08.17.21262138

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (527)
  • Epidemiology (9991)
  • Forensic Medicine (5)
  • Gastroenterology (496)
  • Genetic and Genomic Medicine (2430)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1633)
  • Health Policy (750)
  • Health Systems and Quality Improvement (632)
  • Hematology (247)
  • HIV/AIDS (529)
  • Infectious Diseases (except HIV/AIDS) (11843)
  • Intensive Care and Critical Care Medicine (624)
  • Medical Education (250)
  • Medical Ethics (73)
  • Nephrology (267)
  • Neurology (2266)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (449)
  • Occupational and Environmental Health (532)
  • Oncology (1241)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (727)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (280)
  • Psychiatry and Clinical Psychology (2272)
  • Public and Global Health (4815)
  • Radiology and Imaging (832)
  • Rehabilitation Medicine and Physical Therapy (486)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (123)
  • Urology (99)